Tree Man Cured: Rare Case of Epidermodysplasia Verruciformis

RDR Staff
Published Online: Tuesday, Jan 10, 2017
As we reported earlier, Abul Bajanda has suffered from epidermodysplasia verruciformis much of his adult life. It is an extremely rare disease that creates bark-like warts on his body. In Abul’s case, mostly on his hands.
For the past year, Abul has been receiving treatment – for free – at the Dhaka Medical College hospital in Dhaka, Bangladesh.  And it is now being reported that after 16 surgeries, Abul now has his hands back.
The multiple surgeries removed an estimated 5kg (11 pounds) of growth.
Several news sources have now provided details of the surgery and images of his ‘new’ hands.
Abul has been receiving free treatment at Dhaka Medical College Hospital since his condition came to the attention of doctors a year ago. His wife and daughter has been living at the facility with him for the past 12 months.

Samanta Lal Sen, plastic surgery coordinator at Dhaka Medical College hospital said, “Bajandar’s cure was a remarkable milestone in the history of medical science.”

Dr Sen added, “We operated on him at least 16 times to remove the warts. The hands and feet are now almost fine. He will be discharged within the next 30 days after a couple of minor surgeries to perfect the shape of his hands.”

Twitter explodes

About epidermodysplasia verruciformis
Epidermodysplasia verruciformis (EV) is a rare, inherited disorder that predisposes patients to widespread human papillomavirus (HPV) infection and cutaneous squamous cell carcinomas.
There are over 70 subtypes of HPV that are responsible for causing a wide range of viral warts. In the general population infection with some subtypes of HPV have minimal or no clinical effect, however in patients with EV, infection with these same subtypes can cause flat, wart-like lesions. It has been found that patients with EV have an abnormal or impaired immune response to HPV or wart viruses.

To stay informed on the latest in rare disease news and developments, please sign up for our weekly newsletter at www.raredr.com/newsletter

Latest Articles
Dave Esposito, father of a child with Sanfilippo syndrome, wants the FDA and the pharmaceutical industry to know that their definition of a good outcome measure is different than a parent's definition.
Alexion announced it will stop developing SBC-103 for the treatment of Sanfilippo type B [mucopolysaccharidosis (MPS) IIIB].
A Phase 3b trial assessing agalsidase beta in pediatric Fabry disease male patients shows encouraging results.
A Phase II study testing savolitinib in locally advanced or metastatic pulmonary sarcomatoid carcinoma (PSC) has begun in China.
$vacMongoViewPlus$ $vAR$